SouthState Corp’s ADMA Biologics ADMA Stock Holding History

SouthState Corp’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-950	Closed	-$18.8K	–	1587
2025 Q1	$18.8K	Buy	+950	New	+$16.4K	﹤0.01%	703

Other funds holding ADMA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $59.5B AUM 35.96% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

SouthState Corp's ADMA Position: Q2 2025 in Review

SouthState Corp sold out of ADMA Biologics (ADMA) in Q2 2025, closing a stake of 950 shares — an estimated $18.8K sold.

SouthState Corp first reported a position in ADMA in Q1 2025 and held it in 1 quarter. The position peaked at $18.8K in Q1 2025. 368 funds tracked by Wall St. Rank hold ADMA as of Q2 2025.

SouthState Corp reported no remaining ADMA Biologics position as of Q2 2025 after selling out during the quarter.
SouthState Corp sold 950 ADMA Biologics shares in Q2 2025, an estimated $18.8K.
SouthState Corp first reported a position in ADMA Biologics in Q1 2025 and held it in 1 quarter.
SouthState Corp's ADMA Biologics position peaked at $18.8K in Q1 2025.
368 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2025.

Based on SouthState Corp's 13F filing for Q2 2025, filed 6 Aug 2025.